TürkiyeResearch and clinical trials
7 McArdle patients found in 350 muscle biopsies in Eskişehir; two had developed kidney failure
In Eskişehir, 350 muscle biopsies taken between 2013 and 2024 were reviewed retrospectively.
Inborn errors of metabolism
An inherited muscle disease. The muscles cannot turn their stored sugar into energy. Tiredness, pain and cramps occur in the first minutes of exercise.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Inborn errors of metabolism” group.
The muscles hold a store of sugar called glycogen. When exercise starts, this store is quickly turned into energy. In this disease, the muscle enzyme that does this job is missing. The muscle cannot find enough energy, especially at the start of exercise.
Symptoms usually begin in childhood or the teenage years. They can range from mild to severe.
CK, a muscle enzyme, is measured in the blood. The "second wind" finding helps with the diagnosis. Today, the diagnosis is usually made with a genetic test on a blood sample. In the past, a muscle biopsy and an arm exercise test were used.
There is no approved treatment specific to the disease. Regular light-to-moderate aerobic exercise under a doctor's supervision is helpful. Sudden and very hard exercise is avoided. A diet rich in complex carbohydrates may be recommended. For some people, taking sugar before exercise may be recommended. Research is ongoing. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. The mother and father are usually healthy carriers. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. In marriages between relatives, the chance of carrying the same gene is higher. Genetic counselling is recommended for the family.
Source: MedlinePlus Genetics: Glycogen storage disease type V · NORD: Glycogen Storage Disease Type V
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
For all rare diseases: Nadir Hastalıklar Federasyonu
Links checked on October 8, 2026.
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
TürkiyeResearch and clinical trials
In Eskişehir, 350 muscle biopsies taken between 2013 and 2024 were reviewed retrospectively.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
ClinicalTrials.gov currently lists no active interventional studies for this disease. Last checked: October 7, 2026.
See all studies on ClinicalTrials.gov · Joining clinical trials
EUNew treatments and approvals
In Europe, leriglitazone, taken by mouth, was authorized for cerebral adrenoleukodystrophy.
USANew treatments and approvals
Through the accelerated pathway, the FDA has approved pariglasgene brecaparvovec for glycogen storage disease type Ia.
EuropeResearch and clinical trials
A total of 58 patients from 34 centers in seven European countries were followed.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:368
No separate ICD-11 code; WHO classifies this disease under: 5C51.3
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.